Intercept Pharma (ICPT): Symphony Health Indicates Above Consensus Ocaliva Sales - Wedbush
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) and sees growing Ocaliva sales and multiple catalysts in the next 6-18 months.
Symphony Health (SH) estimated just over $5 million for Q3 OCA sales— above consensus of $3.5 million. Based on the monthly estimates for OCA sales for PBC, the analyst estimates Q3 OCA sales of at least $5 million, ahead of the Thomson consensus of ~$3.5 million (range $1.6 million to $7.2 million).
There is no change to estimates at this time since Ocaliva was only launched in June and there is not a consistent capture rate for the Symphony Health monthly estimates compared with reported sales.
No change to the price target of $239.
Shares of Intercept Pharmaceuticals closed at $154.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Chipotle Mexican Grill (CMG) to Neutral; 'New Normal'
- Needham & Company Retains Buy Rating on Nielsen (NLSN) Amid Disappointing Results and Sell-Off
- FBR Capital Sees Under Armour (UA) Sell-Off as Buying Opportunity
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesLiana Moussatos
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!